(Q35020544)

5 August 2017

1 reference

title

Niacin extended-release/lovastatin: combination therapy for lipid disorders (English)

1 reference

5 August 2017

1 reference

Yong S K Moon

1

1 reference

PubMed ID

12472373

5 August 2017

Moti L Kashyap

series ordinal

2

1 reference

PubMed ID

12472373

5 August 2017

language of work or name

English

0 references

publication date

1 December 2002

1 reference

Expert Opinion on Pharmacotherapy

5 August 2017

1 reference

5 August 2017

3

1 reference

5 August 2017

12

1 reference

5 August 2017

1763-1771

1 reference

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

5 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1763

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1763

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1763

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1763

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1763

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1763

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1763

Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1763

Comparison of extended-release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1763

Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1763

Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1763

The benefits of niacin in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1763

Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1763

Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1763

Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1763

Mechanism of action of niacin on lipoprotein metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1763

Differential effects of nicotinic acid in subjects with different LDL subclass patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1763

Homocysteine and cardiovascular disease: current evidence and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1763

Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1763

Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1763

HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1763

Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1763

A receptor-mediated pathway for cholesterol homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1763

Lovastatin and extended-release niacin combination product: the first drug combination for the management of hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1763

Increased beta-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1763

Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1763

Differences in metabolism of time-release and unmodified nicotinic acid: Explanation of the differences in hypolipidemic action?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1763

10.1517/14656566.3.12.1763

21 January 2018

Identifiers

DOI

1 reference

5 August 2017

1 reference

PubMed ID

12472373